Mek inhibiting oxa- and thia-diazol-2-yl phenylamine...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 271/113 (2006.01) A61K 31/4245 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) C07D 249/08 (2006.01) C07D 249/14 (2006.01) C07D 271/10 (2006.01) C07D 285/135 (2006.01) C07D 413/04 (2006.01) C07D 413/12 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01)

Patent

CA 2509405

This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl~phenyl)- amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPKIERK Kinase ("MEK") enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.

L'invention concerne des composés substitués de phényl-(2-[1,3,4]thiadiazol-2-yl-phényl)-amine et (2-[1,3,4]Oxadiazol-2-yl-phényl)phényl-amine qui fonctionnent comme des inhibiteurs d'enzymes de kinase MAPK/ERK Kinase ("MEK") ainsi que des compositions pharmaceutiques et des procédés de leur utilisation dans l'immunomodulation, pour traiter ou soulager des inflammations et des maladies telles que cancer ou la resténose.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Mek inhibiting oxa- and thia-diazol-2-yl phenylamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mek inhibiting oxa- and thia-diazol-2-yl phenylamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mek inhibiting oxa- and thia-diazol-2-yl phenylamine... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1612661

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.